Related Experiment Video

Updated: Mar 9, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.8K

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

Lorena Incorvaia1, Francesc Passiglia1, Sergio Rizzo1

  • 1Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.

Oncotarget
|January 6, 2017
PubMed

Insights

PARP inhibitors show promise in treating BRCA-mutated cancers like ovarian and breast cancer. This review covers their efficacy, resistance mechanisms, and potential in new clinical trials for various tumors with homologous recombination deficiency.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRCA mutations confer sensitivity to PARP inhibitors via synthetic lethality.
  • PARP inhibitors are developed as anticancer agents, with initial focus on ovarian and breast cancers.
  • Clinical studies now extend to other tumor types with BRCA mutations and homologous recombination deficiency (HRD).

Purpose of the Study:

  • To review the biological basis of PARP inhibition.
  • To summarize key clinical trial results of PARP inhibitors.
  • To elucidate resistance mechanisms for improved therapeutic strategies.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of clinical trial data for PARP inhibitors in various cancers.
  • Investigation of molecular mechanisms of PARP inhibitor resistance.

Main Results:

  • PARP inhibitors demonstrate significant efficacy in BRCA-mutated ovarian and breast cancers.
  • Promising results are emerging in other tumor types with BRCA mutations and HRD.
  • Understanding of primary and acquired resistance mechanisms is advancing.

Conclusions:

  • PARP inhibitors represent a key therapeutic strategy for BRCA-mutated and HRD-positive cancers.
  • Further research into resistance mechanisms will guide the development of next-generation treatments.
  • Combination therapies and expanded indications are areas of active clinical investigation.
Keywords:
BRCA1-2PARP inhibitorsresistance

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.2K